 Talmadge King, JR., MD
|
| Title | Professor |
|---|
| School | UCSF Chancellor/EVC/FAS |
|---|
| Department | Other |
|---|
| Address | Parnassus
|
|---|
| Phone | 415-476-0909 |
|---|
|
|
 Biography | Foundation of the American Thoracic Society | 2012 | | Breathing for Life Award | | Gustavus Adolphus College | 2012 | | Sesquicentennial Award | | American Academy of Arts and Sciences | 2011 | | Fellow | | American College of Physicians | 2010 | | Master | | Gustavus Alumni Association, Gustavus Adolphus College | 2008 | | Alumni Citation | | American Thoracic Society | 2007 | | Trudeau Medal | | Institute of Medicine, National Academy of Sciences | 2004 | | Member | | Public Advisory Roundtable of the American Thoracic Society | 2003 | | PAR Excellence Award | | Association of American Physicians | 1998 | | Member | | California Thoracic Society | 1998 | | Elected honorary member | | Colorado Thoracic Society, American Lung Association of Colorado | 1998 | | Member. Colorado Pulmonary Hall of Fame | | The Fleischner Society | 1997 | | Member | | Western Association of Physicians | 1993 | | Member | | American Lung Association of Colorado | 1992 | | James J. Waring Award For Outstanding Leadership in the Treatment of Lung Disease | | American College of Physicians | 1986 | | Fellow | | American College of Chest Physicians | 1984 | | Fellow | | Alumni Association, Gustavus Adolphus College | 1980 | | First Decade Award for Early Achievement | | Gustavus Adolphus College | 1970 | | Guild of St. Ansger Honor Society |
Overview Dr. Talmadge E. King, Jr. is chair of the Department of Medicine at the University of California, San Francisco where he oversees a department of more than 550 full-time faculty, over 500 volunteer clinical faculty, 180 residents, 238 fellows and over 1000 support staff. His focus in patient care is interstitial lung diseases, in particular idiopathic pulmonary fibrosis, sarcoidosis, connective tissue disease, hypersensitivity pneumonitis, drug-induced lung fibrosis and other rare diffuse lung disorders. King's research interests include pathogenesis, diagnosis and management of inflammatory and immunologic lung disease. He has co-authored eight books including the acclaimed reference book, "Interstitial Lung Disease," now in its fourth edition.
King earned a medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver. He is a member of the American Academy of Arts and Sciences, Institute of Medicine, National Academy of Sciences, Association of American Physicians, American Clinical and Climatological Association and Fleischner Society and is a master of the American College of Physicians and fellow he American College of Chest Physicians. He holds the Julius R. Krevans Distinguished Professorship in Internal Medicine and won the 2007 Trudeau Medal, the highest honor of the American Lung Association and American Thoracic Society.
Research Interests
His overall focus has been on understanding the pathogenesis, diagnosis and management of inflammatory and immunology lung injury. Another aim is to develop and evaluate methods that can serially identify the presence and extent of disease activity in these patients.
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Researchers can login to make corrections and additions, or contact us for help.
-
Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013 Feb; 107(2):249-55.
-
Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012 Aug 15; 186(4):314-24.
-
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24; 366(21):1968-77.
-
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15; 156(10):684-91.
-
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15; 185(10):1044-8.
-
Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012 May; 67(5):407-11.
-
King TE, Collard HR, Richeldi L. Interstitial lung diseases. Preface. Clin Chest Med. 2012 Mar; 33(1):xiii.
-
Lee JS, Song JW, Wolters PJ, Elicker BM, King TE, Kim DS, Collard HR. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012 Feb; 39(2):352-8.
-
du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1382-9.
-
du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Aug 15; 184(4):459-66.
-
King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 3; 378(9807):1949-61.
-
Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1390-4.
-
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21; 377(9779):1760-9.
-
King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 1; 184(1):92-9.
-
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15; 183(6):788-824.
-
King TE. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011 Mar 10; 364(10):968-70.
-
du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011 May 1; 183(9):1231-7.
-
Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15; 183(4):431-40.
-
Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE, Horne FM, Nayfield SG, Reynolds HY, Schmader KE, Toews GB, High KP. Workshop on idiopathic pulmonary fibrosis in older adults. Chest. 2010 Sep; 138(3):693-703.
-
Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. J Occup Environ Med. 2010 Jun; 52(6):647-52.
-
Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010 Jul; 299(1):L3-7.
-
Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung. 2010 Apr; 188(2):143-9.
-
Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010 Apr; 123(4):304-11.
-
Levinson W, King TE, Goldman L, Goroll AH, Kessler B. Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med. 2010 Mar 11; 362(10):948-52.
-
Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010 Feb; 65(2):173-7.
-
Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, Lee JS, King TE, Collard HR. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010 Jun; 35(6):1322-8.
-
Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009 Nov; 136(5):1397-405.
-
Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010 Feb; 104(2):296-304.
-
Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE, Malhotra A, Parsons PE. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. Am J Respir Crit Care Med. 2009 Aug 15; 180(4):290-5.
-
Raghu G, King TE, Behr J, Brown KK, du Bois RM, Leconte I, Roux S, Swigris J. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J. 2010 Jan; 35(1):118-23.
-
de Kleijn WP, Elfferich MD, De Vries J, Jonker GJ, Lower EE, Baughman RP, King TE, Drent M. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul; 26(2):92-7.
-
King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009 Jul 18; 374(9685):222-8.
-
Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009 Jun; 135(6):1557-63.
-
King TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2008 Nov; 9(11):1171-9.
-
Kinder BW, King TE. Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. Am J Respir Crit Care Med. 2008 Jun 1; 177(11):1292-3; author reply 1293.
-
Collard HR, King TE. Idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia should stay separate. Eur Respir J. 2008 May; 31(5):1141-2; author reply 1142-3.
-
Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Müller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1338-47.
-
Wilson JW, du Bois RM, King TE. Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis. Thorax. 2008 Mar; 63(3):285-7.
-
Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. 2008 Jan; 133(1):226-32.
-
du Bois R, King TE. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax. 2007 Nov; 62(11):1008-12.
-
King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Jan 1; 177(1):75-81.
-
Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008 Jan; 102(1):150-5.
-
Kinder BW, Freemer MM, King TE, Lum RF, Nititham J, Taylor K, Edberg JC, Bridges SL, Criswell LA. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum. 2007 Aug; 56(8):2679-86.
-
Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 Oct 1; 176(7):636-43.
-
Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007 Oct 1; 176(7):691-7.
-
Gotway MB, Freemer MM, King TE. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax. 2007 Jun; 62(6):546-53.
-
Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007; 2(5):e482.
-
Collard HR, Loyd JE, King TE, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007 Sep; 101(9):2011-6.
-
Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE, Brown KK. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest. 2007 Mar; 131(3):664-71.
-
Calfee CS, Shah SJ, Wolters PJ, Saint S, King TE. Clinical problem-solving. Anchors away. N Engl J Med. 2007 Feb 1; 356(5):504-9.
-
Flaherty KR, Andrei AC, King TE, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, Travis WD, Vyskocil J, Wadenstorer FA, Wilt J, Toews GB, Murray S, Martinez FJ. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007 May 15; 175(10):1054-60.
-
Zamora AC, Collard HR, Wolters PJ, Webb WR, King TE. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J. 2007 Jan; 29(1):210-4.
-
Kinder BW, Collard HR, King TE. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest. 2006 Jul; 130(1):302-3.
-
Kim DS, Collard HR, King TE. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006 Jun; 3(4):285-92.
-
Walter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006 Jun; 3(4):330-8.
-
Perez RL, Kimani AP, King TE, Aguayo SM, Roman J. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration. 2007; 74(3):297-303.
-
Wesson DE, King TE, Todd RF, Torres EA, Hellmann DB, Flack JM, Dubose TD, Schuster VL. Achieving diversity in academic internal medicine: recommendations for leaders. Am J Med. 2006 Jan; 119(1):76-81.
-
Shah NR, Noble P, Jackson RM, King TE, Nathan SD, Padilla M, Raghu G, Rhodes MB, Schwarz M, Tino G, Dubois RW. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct; 22(3):167-74.
-
Girod CE, King TE. COPD: a dust-induced disease? Chest. 2005 Oct; 128(4):3055-64.
-
Freemer MM, King TE, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis. 2006 May; 65(5):581-4.
-
King TE. Idiopathic interstitial pneumonias: translating our current understanding into novel therapies. Exp Lung Res. 2005 Sep; 31 Suppl 1:41-6.
-
Lynch DA, Travis WD, Müller NL, Galvin JR, Hansell DM, Grenier PA, King TE. Idiopathic interstitial pneumonias: CT features. Radiology. 2005 Jul; 236(1):10-21.
-
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):963-7.
-
Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE, Bradford WZ, Schwartz DA, Richard Webb W. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15; 172(4):488-93.
-
King TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005 Aug 1; 172(3):268-79.
-
King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):171-7.
-
King TE, Wheeler MB. Inequality in health care: unjust, inhumane, and unattended! Ann Intern Med. 2004 Nov 16; 141(10):815-7.
-
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004 Oct 15; 170(8):904-10.
-
Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, Brown KK. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest. 2004 Jun; 125(6):2169-74.
-
Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med. 2004 May 15; 116(10):662-8.
-
King TE, Dickinson TA, DuBose TD, Flack JM, Hellmann DB, Pamies RJ, Todd RF, Torres EA, Wesson DE. The case for diversity in academic internal medicine. Am J Med. 2004 Feb 15; 116(4):284-9.
-
Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004 Jan 8; 350(2):125-33.
-
King TE. Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. Trans Am Clin Climatol Assoc. 2004; 115:43-76; discussion 76-8.
-
Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Müller N, Schwartz DA, King TE, Lynch JP, Hegele R, Waldron J, Colby TV, Hogg JC. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003 Oct; 124(4):1215-23.
-
King TE. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Semin Respir Crit Care Med. 2003 Oct; 24(5):567-76.
-
Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest. 2003 Sep; 124(3):929-35.
-
Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003 Sep 1; 168(5):538-42.
-
Collard HR, King TE. Demystifying idiopathic interstitial pneumonia. Arch Intern Med. 2003 Jan 13; 163(1):17-29.
-
Inoue Y, King TE, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002 Sep 1; 166(5):765-73.
-
Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE, Leinwand LA, Liotta L, Martin GR, Schwartz DA, Schultz GS, Wagner CR, Musson RA. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med. 2002 Jul 15; 166(2):236-46.
-
King TE. Nonspecific interstitial pneumonia and systemic sclerosis. Am J Respir Crit Care Med. 2002 Jun 15; 165(12):1578-9.
-
King TE. Racial disparities in clinical trials. N Engl J Med. 2002 May 2; 346(18):1400-2.
-
Vourlekis JS, Schwarz MI, Cool CD, Tuder RM, King TE, Brown KK. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am J Med. 2002 Apr 15; 112(6):490-3.
-
Greene KE, King TE, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar; 19(3):439-46.
-
Freemer M, King TE. The ACCESS study: characterization of sarcoidosis in the United States. Am J Respir Crit Care Med. 2001 Nov 15; 164(10 Pt 1):1754-5.
-
Martinez JA, Nishimura C, Guatura SB, Sato E, King TE. Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatol Int. 2001 Nov; 21(3):122-6.
-
Collard HR, King TE. Lung biopsy in patients with usual interstitial pneumonia. Eur Respir J. 2001 Nov; 18(5):895-8.
-
King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001 Oct 1; 164(7):1171-81.
-
King TE, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA, Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001 Sep 15; 164(6):1025-32.
-
Collard HR, King TE. The clinical significance of histopathologic subgroups in idiopathic interstitial pneumonia: is surgical lung biopsy essential? Semin Respir Crit Care Med. 2001 Aug; 22(4):347-56.
-
Hunninghake GW, Zimmerman MB, Schwartz DA, King TE, Lynch J, Hegele R, Waldron J, Colby T, Müller N, Lynch D, Galvin J, Gross B, Hogg J, Toews G, Helmers R, Cooper JA, Baughman R, Strange C, Millard M. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001 Jul 15; 164(2):193-6.
-
Collard HR, King TE. Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. Am J Med. 2001 Mar; 110(4):326-8.
-
Costabel U, King TE. International consensus statement on idiopathic pulmonary fibrosis. Eur Respir J. 2001 Feb; 17(2):163-7.
-
Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001 Jan 16; 134(2):136-51.
-
Vourlekis JS, Brown KK, Cool CD, Young DA, Cherniack RM, King TE, Schwarz MI. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore). 2000 Nov; 79(6):369-78.
-
King TE. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med. 2000 Mar 30; 342(13):974-5.
-
King TE, Brunetta P. Racial disparity in rates of surgery for lung cancer. N Engl J Med. 1999 Oct 14; 341(16):1231-3.
-
Rose CS, Martyny JW, Newman LS, Milton DK, King TE, Beebe JL, McCammon JB, Hoffman RE, Kreiss K. "Lifeguard lung": endemic granulomatous pneumonitis in an indoor swimming pool. Am J Public Health. 1998 Dec; 88(12):1795-800.
-
King TE. Update in pulmonary medicine. Ann Intern Med. 1998 Nov 15; 129(10):806-12.
-
Cohen AJ, King TE, Gilman LB, Magill-Solc C, Miller YE. High expression of neutral endopeptidase in idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells. Am J Respir Crit Care Med. 1998 Nov; 158(5 Pt 1):1593-9.
-
Uh ST, Inoue Y, King TE, Chan ED, Newman LS, Riches DW. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998 Nov; 158(5 Pt 1):1626-35.
-
Fontenot A, Jennings C, King TE. Pulmonary opacities and glomerulonephritis in a 15-year-old boy. Chest. 1998 Feb; 113(2):525-7.
-
Crausman RS, King TE. Pulmonary vascular involvement in pulmonary histiocytosis X. Chest. 1997 Dec; 112(6):1714.
-
Martinez JA, King TE, Brown K, Jennings CA, Borish L, Mortenson RL, Khan TZ, Bost TW, Riches DW. Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol. 1997 Sep; 273(3 Pt 1):L676-83.
-
Tomioka R, King TE. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med. 1997 Mar; 155(3):1011-20.
-
Jennings CA, King TE, Tuder R, Cherniack RM, Schwarz MI. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med. 1997 Mar; 155(3):1101-9.
-
Inoue Y, King TE, Tinkle SS, Dockstader K, Newman LS. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol. 1996 Dec; 149(6):2037-54.
-
King TE. A lung biopsy is necessary in the management of ANCA-positive patients with chest roentgenographic abnormalities. Sarcoidosis Vasc Diffuse Lung Dis. 1996 Oct; 13(3):238-40.
-
Fitzgerald JE, King TE, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med. 1996 Aug; 154(2 Pt 1):497-503.
-
Crausman RS, Jennings CA, Mortenson RL, Ackerson LM, Irvin CG, King TE. Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. Am J Respir Crit Care Med. 1996 Apr; 153(4 Pt 1):1368-76.
-
Inoue Y, Cornebise M, Daniloff E, Lloyd J, Tinkle S, King TE, Newman LS. Mast cell-associated basic fibroblast growth factor in the fibrotic response to environmental toxins. The Beryllium Model. Chest. 1996 Mar; 109(3 Suppl):43S-44S.
-
Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King TE. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med. 1996 Jan; 153(1):426-35.
-
Crausman RS, Lynch DA, Mortenson RL, King TE, Irvin CG, Hale VA, Newell JD. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest. 1996 Jan; 109(1):131-7.
-
Bernstein SM, Newell JD, Adamczyk D, Mortenson RL, King TE, Lynch DA. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med. 1995 Dec; 152(6 Pt 1):2138-43.
-
Ohta K, Mortenson RL, Clark RA, Hirose N, King TE. Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995 Nov; 152(5 Pt 1):1659-65.
-
Lynch DA, Newell JD, Logan PM, King TE, Müller NL. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol. 1995 Oct; 165(4):807-11.
-
McCormack FX, King TE, Bucher BL, Nielsen L, Mason RJ, McCormac FX. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995 Aug; 152(2):751-9.
-
Crystal RG, Mastrangeli A, Sanders A, Cooke J, King T, Gilbert F, Henschke C, Pascal W, Herena J, Harvey BG, et al. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis. Hum Gene Ther. 1995 May; 6(5):667-703.
-
Janson RW, Hance KR, King TE. Human alveolar macrophages produce predominantly the 35-kD pro-forms of interleukin-1 alpha and interleukin-1 beta when stimulated with lipopolysaccharide. Am J Respir Crit Care Med. 1995 May; 151(5):1613-20.
-
Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron JA, Ackerson L, Schwarz MI, King TE. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995 Apr; 151(4):1180-8.
-
Forrester JM, Wang Y, Ricalton N, Fitzgerald JE, Loveless J, Newman LS, King TE, Kotzin BL. TCR expression of activated T cell clones in the lungs of patients with pulmonary sarcoidosis. J Immunol. 1994 Nov 1; 153(9):4291-302.
-
Newman LS, Bobka C, Schumacher B, Daniloff E, Zhen B, Mroz MM, King TE. Compartmentalized immune response reflects clinical severity of beryllium disease. Am J Respir Crit Care Med. 1994 Jul; 150(1):135-42.
-
Cohen AJ, King TE, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med. 1994 Jun; 149(6):1670-5.
-
Garg K, Lynch DA, Newell JD, King TE. Proliferative and constrictive bronchiolitis: classification and radiologic features. AJR Am J Roentgenol. 1994 Apr; 162(4):803-8.
-
Wade JF, King TE. Dyspnea, cough, and interstitial lung disease in a 32-year-old smoker. Chest. 1994 Jan; 105(1):265-7.
-
Carré PC, King TE, Mortensen R, Riches DW. Cryptogenic organizing pneumonia: increased expression of interleukin-8 and fibronectin genes by alveolar macrophages. Am J Respir Cell Mol Biol. 1994 Jan; 10(1):100-5.
-
King TE. Respiratory bronchiolitis-associated interstitial lung disease. Clin Chest Med. 1993 Dec; 14(4):693-8.
-
King TE. Overview of bronchiolitis. Clin Chest Med. 1993 Dec; 14(4):607-10.
-
Kraft M, Mortenson RL, Colby TV, Newman L, Waldron JA, King TE. Cryptogenic constrictive bronchiolitis. A clinicopathologic study. Am Rev Respir Dis. 1993 Oct; 148(4 Pt 1):1093-101.
-
Wade JF, King TE. Infiltrative and interstitial lung disease in the elderly patient. Clin Chest Med. 1993 Sep; 14(3):501-21.
-
Janson RW, King TE, Hance KR, Arend WP. Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. Am Rev Respir Dis. 1993 Aug; 148(2):495-503.
-
Schwarz MI, Mortenson RL, Colby TV, Waldron JA, Lynch DA, Hutt MP, Cherniack RM, King TE. Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis. 1993 Aug; 148(2):507-11.
-
Forrester JM, Newman LS, Wang Y, King TE, Kotzin BL. Clonal expansion of lung V delta 1+ T cells in pulmonary sarcoidosis. J Clin Invest. 1993 Jan; 91(1):292-300.
-
King TE. Restrictive lung disease in pregnancy. Clin Chest Med. 1992 Dec; 13(4):607-22.
-
Buschman DL, Gamsu G, Waldron JA, Klein JS, King TE. Chronic hypersensitivity pneumonitis: use of CT in diagnosis. AJR Am J Roentgenol. 1992 Nov; 159(5):957-60.
-
Aguayo SM, Miller YE, Waldron JA, Bogin RM, Sunday ME, Staton GW, Beam WR, King TE. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med. 1992 Oct 29; 327(18):1285-8.
-
Hyde DM, King TE, McDermott T, Waldron JA, Colby TV, Thurlbeck WM, Flint WM, Ackerson L, Cherniack RM. Idiopathic pulmonary fibrosis. Quantitative assessment of lung pathology. Comparison of a semiquantitative and a morphometric histopathologic scoring system. Am Rev Respir Dis. 1992 Oct; 146(4):1042-7.
-
Low RB, Giancola MS, King TE, Chapitis J, Vacek P, Davis GS. Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1992 Sep; 146(3):701-6.
-
Lynch DA, Rose CS, Way D, King TE. Hypersensitivity pneumonitis: sensitivity of high-resolution CT in a population-based study. AJR Am J Roentgenol. 1992 Sep; 159(3):469-72.
-
King TE, Mortenson RL. Cryptogenic organizing pneumonitis. The North American experience. Chest. 1992 Jul; 102(1 Suppl):8S-13S.
-
King TE, Mortenson RL. Bronchoalveolar lavage in patients with connective tissue disease. J Thorac Imaging. 1992 Jun; 7(3):26-48.
-
Kulwiec EL, Lynch DA, Aguayo SM, Schwarz MI, King TE. Imaging of pulmonary histiocytosis X. Radiographics. 1992 May; 12(3):515-26.
-
Aguayo SM, King TE, Kane MA, Sherritt KM, Silvers W, Nett LM, Petty TL, Miller YE. Urinary levels of bombesin-like peptides in asymptomatic cigarette smokers: a potential risk marker for smoking-related diseases. Cancer Res. 1992 May 1; 52(9 Suppl):2727s-2731s.
-
Carré PC, Mortenson RL, King TE, Noble PW, Sable CL, Riches DW. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest. 1991 Dec; 88(6):1802-10.
-
Hanley ME, King TE, Schwarz MI, Watters LC, Shen AS, Cherniack RM. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis. 1991 Nov; 144(5):1102-6.
-
Cherniack RM, Colby TV, Flint A, Thurlbeck WM, Waldron J, Ackerson L, King TE. Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis. 1991 Oct; 144(4):892-900.
-
Alford CE, King TE, Campbell PA. Role of transferrin, transferrin receptors, and iron in macrophage listericidal activity. J Exp Med. 1991 Aug 1; 174(2):459-66.
-
McCormack FX, King TE, Voelker DR, Robinson PC, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis. 1991 Jul; 144(1):160-6.
-
King TE. Diagnostic advances in idiopathic pulmonary fibrosis. Chest. 1991 Jul; 100(1):238-41.
-
Leslie K, King TE, Low R. Smooth muscle actin is expressed by air space fibroblast-like cells in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Chest. 1991 Mar; 99(3 Suppl):47S-48S.
-
Shaw RJ, Benedict SH, Clark RA, King TE. Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma. Am Rev Respir Dis. 1991 Jan; 143(1):167-73.
-
Aguayo SM, King TE, Waldron JA, Sherritt KM, Kane MA, Miller YE. Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma. J Clin Invest. 1990 Sep; 86(3):838-44.
-
Buschman DL, Waldron JA, King TE. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis. 1990 Aug; 142(2):458-61.
-
Goldstein RA, Rohatgi PK, Bergofsky EH, Block ER, Daniele RP, Dantzker DR, Davis GS, Hunninghake GW, King TE, Metzger WJ, et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis. 1990 Aug; 142(2):481-6.
-
Tazelaar HD, Myers JL, Drage CW, King TE, Aguayo S, Colby TV. Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest. 1990 May; 97(5):1032-6.
-
Panos RJ, Mortenson RL, Niccoli SA, King TE. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990 Apr; 88(4):396-404.
-
Last JA, King TE, Nerlich AG, Reiser KM. Collagen cross-linking in adult patients with acute and chronic fibrotic lung disease. Molecular markers for fibrotic collagen. Am Rev Respir Dis. 1990 Feb; 141(2):307-13.
-
Aguayo SM, Kane MA, King TE, Schwarz MI, Grauer L, Miller YE. Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest. 1989 Oct; 84(4):1105-13.
-
Newman LS, Kreiss K, King TE, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis. 1989 Jun; 139(6):1479-86.
-
Leff JA, King TE. Cavitary lung disease with skin lesions. Chest. 1989 Feb; 95(2):457-8.
-
King TE. Bronchiolitis obliterans. Lung. 1989; 167(2):69-93.
-
Savici D, Campbell PA, King TE. Bronchoalveolar macrophages from patients with idiopathic pulmonary fibrosis are unable to kill facultative intracellular bacteria. Am Rev Respir Dis. 1989 Jan; 139(1):22-7.
-
Badesch DB, King TE, Schwarz MI. Acute eosinophilic pneumonia: a hypersensitivity phenomenon? Am Rev Respir Dis. 1989 Jan; 139(1):249-52.
-
King TE, Savici D, Campbell PA. Phagocytosis and killing of Listeria monocytogenes by alveolar macrophages: smokers versus nonsmokers. J Infect Dis. 1988 Dec; 158(6):1309-16.
-
Dunn TL, Watters LC, Hendrix C, Cherniack RM, Schwarz MI, King TE. Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. Am J Med. 1988 Aug; 85(2):221-4.
-
Willcox M, Kervitsky A, Watters LC, King TE. Quantification of cells recovered by bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method. Am Rev Respir Dis. 1988 Jul; 138(1):74-80.
-
Robinson PC, Watters LC, King TE, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. Am Rev Respir Dis. 1988 Mar; 137(3):585-91.
-
Shen A, Iseman MD, Waldron JA, King TE. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest. 1987 May; 91(5):782-5.
-
Watters LC, Schwarz MI, Cherniack RM, Waldron JA, Dunn TL, Stanford RE, King TE. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis. 1987 Mar; 135(3):696-704.
-
Watters LC, King TE, Cherniack RM, Waldron JA, Stanford RE, Willcox ML, Christopher KL, Schwarz MI. Bronchoalveolar lavage fluid neutrophils increase after corticosteroid therapy in smokers with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1986 Jan; 133(1):104-9.
-
Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1986 Jan; 133(1):97-103.
-
Libby LS, King TE, LaForce FM, Schwarz MI. Pulmonary cavitation following pulmonary infarction. Medicine (Baltimore). 1985 Sep; 64(5):342-8.
-
King TE, Schwarz MI, Mathew M. Waldenström's macroglobulinemia: report of a case with pulmonary involvement and recurrent pneumococcal sepsis after pneumococcal vaccination. J Natl Med Assoc. 1984 Feb; 76(2):184-6, 189.
-
Good JT, King TE, Antony VB, Sahn SA. Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies. Chest. 1983 Dec; 84(6):714-8.
-
Stelzner TJ, King TE, Antony VB, Sahn SA. The pleuropulmonary manifestations of the postcardiac injury syndrome. Chest. 1983 Oct; 84(4):383-7.
-
King TE, Stelzner TJ, Sahn SA. Cardiac tamponade complicating the postpericardiotomy syndrome. Chest. 1983 Mar; 83(3):500-3.
-
King TE, Christopher KL, Schwarz MI. Multiple pulmonary chondromatous hamartomas. Hum Pathol. 1982 May; 13(5):496-7.
-
King TE, Fisher J, Schwarz MI, Patzelt LH. Bilateral hilar adenopathy: an unusual presentation of renal cell carcinoma. Thorax. 1982 Apr; 37(4):317-8.
-
Kaplan RL, Schocket AL, King TE, Maulitz RM, Good JT, Stanford RE, Sahn SA. A model of immune complex-mediated pleuropulmonary injury; evidence of deposition of circulating immune complexes in the lung. Am J Pathol. 1980 Jul; 100(1):115-30.
-
King TE, Schwarz MI, Dreisin RE, Pratt DS, Theofilopoulos AN. Circulating immune complexes in pulmonary eosinophilic granuloma. Ann Intern Med. 1979 Sep; 91(3):397-9.
|
Talmadge's Networks
Click the "See All" links for more information and interactive visualizations!
Related Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Related Authors People who share similar concepts with this person. _
|
